140 related articles for article (PubMed ID: 32823294)
21. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
22. Molecular imaging and biochemical response assessment after a single cycle of [
Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F
Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047
[No Abstract] [Full Text] [Related]
23. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
24. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
25. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
[TBL] [Abstract][Full Text] [Related]
26. First Clinical Results for PSMA-Targeted α-Therapy Using
Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
[TBL] [Abstract][Full Text] [Related]
27.
Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
Kim YJ; Kim YI
Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428
[TBL] [Abstract][Full Text] [Related]
29. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
30. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.
Ghodsirad MA; Pirayesh E; Akbarian R; Javanmard B; Kaghazchi F; Tavakoli M; Fattahi K
Urol J; 2020 Jun; 17(4):374-378. PubMed ID: 32281092
[TBL] [Abstract][Full Text] [Related]
32. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Paller CJ; Piana D; Eshleman JR; Riel S; Denmeade SR; Isaacsson Velho P; Rowe SP; Pomper MG; Antonarakis ES; Luo J; Eisenberger MA
Prostate; 2019 Oct; 79(14):1597-1603. PubMed ID: 31361358
[TBL] [Abstract][Full Text] [Related]
33.
Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):81-91. PubMed ID: 27506431
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen.
Rathore R; Rangrej SB; Kieme I; Carvalho V; King K; Amadou Y; McKinley J; Masawi A
Cureus; 2023 Apr; 15(4):e37778. PubMed ID: 37214073
[TBL] [Abstract][Full Text] [Related]
35. Clinical Outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
36. Dosimetry of
Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
[No Abstract] [Full Text] [Related]
37. Value of post-therapy
Tuncel M; Telli T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750
[TBL] [Abstract][Full Text] [Related]
38.
Ballal S; Yadav MP; Sahoo RK; Tripathi M; Dwivedi SN; Bal C
Prostate; 2021 Jun; 81(9):580-591. PubMed ID: 33905559
[TBL] [Abstract][Full Text] [Related]
39. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
[TBL] [Abstract][Full Text] [Related]
40. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Rahbar K; Ahmadzadehfar H; Kratochwil C; Haberkorn U; Schäfers M; Essler M; Baum RP; Kulkarni HR; Schmidt M; Drzezga A; Bartenstein P; Pfestroff A; Luster M; Lützen U; Marx M; Prasad V; Brenner W; Heinzel A; Mottaghy FM; Ruf J; Meyer PT; Heuschkel M; Eveslage M; Bögemann M; Fendler WP; Krause BJ
J Nucl Med; 2017 Jan; 58(1):85-90. PubMed ID: 27765862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
